Ivan Božin (Ivan Bozin)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Mass Spectrometry

Multiple Sclerosis

Top Venues

Advances in therapy

Journal of comparative effectiveness research

This page only lists publications with an associated author ORCID identifier.

Publications

Tammy Jiang, Mathura Shanmugasundaram, Ivan Božin, Mark S Freedman, James B Lewin, Changyu Shen, Tjalf Ziemssen, Douglas L Arnold
Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons. Journal of comparative effectiveness research (2024)
James D Bowen, Jessica Stulc, Samuel F Hunter, Hailu Chen, James B Lewin, Matthew Scaramozza, Ivan Božin, Florian Then Bergh
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study. Advances in therapy 41 (8) (2024)
James D Bowen, Jessica Stulc, Samuel F Hunter, Hailu Chen, James B Lewin, Matthew Scaramozza, Ivan Božin, Florian Then Bergh
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study. Advances in therapy 41 (8) (2024)
James D Bowen, Jessica Stulc, Samuel F Hunter, Hailu Chen, James B Lewin, Matthew Scaramozza, Ivan Božin, Florian Then Bergh
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study. Advances in therapy (2024)
James D Bowen, Jessica Stulc, Samuel F Hunter, Hailu Chen, James B Lewin, Matthew Scaramozza, Ivan Božin, Florian Then Bergh
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study. Advances in therapy 41 (8) (2024)